Specify a stock or a cryptocurrency in the search bar to get a summary
Dianthus Therapeutics Inc.
DNTHDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Address: 7 Times Square, New York, NY, United States, 10036
Analytics
WallStreet Target Price
50.1 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DNTH
Dividend Analytics DNTH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DNTH
Stock Valuation DNTH
Financials DNTH
Results | 2019 | Dynamics |